Homology Medicines Appoints Brad Smith as Chief Financial Officer

BEDFORD, Mass., April 4, 2017 – Homology Medicines, Inc., a genetic medicines company translating proprietary, next generation gene editing and gene therapy technologies into novel treatments for patients, announced today that Brad Smith has been appointed Chief Financial Officer. Mr. Smith has more than 27 years of experience leading business and financial operations for private and public companies in the biotechnology and healthcare industry, including private equity financings, initial public offerings, investor relations, business development initiatives and strategic planning. In this role, Mr. Smith joins a management team with a proven track record in delivering novel therapies for patients with rare genetic disorders.

“Brad is a great addition to our team and brings the strong financial and business expertise that Homology Medicines will leverage as we continue to move our lead gene therapy and gene editing programs forward toward the clinic,” said Arthur Tzianabos, Ph.D., Chief Executive Officer of Homology Medicines. “Brad’s broad industry perspective, understanding of the crucial operational aspects of a growing organization and his demonstrated ability to manage multiple strategic functions will serve us well as we focus on rapid execution that builds value and improves the lives of patients.”

Prior to joining Homology Medicines, Mr. Smith served as CFO of Ocular Therapeutix, Inc., where he led the company’s strategic financings, including an initial public offering and subsequent follow-on offerings, and completed a development and commercialization agreement with a major biopharmaceutical company. Previously, Mr. Smith served as CFO of several other healthcare companies, including OmniGuide Surgical, NeuroMetrix, Inc., SYNARC, PatientKeeper, Inc. and Focal, Inc. During his career, he has been instrumental in raising more than $450 million in private and public equity and debt financing, has played a key role in business development and strategic planning functions and has successfully guided three companies through the initial public offering process. Mr. Smith holds a B.S. in Biology from Tufts University and an M.B.A. from the Whittemore School at the University of New Hampshire, and he became a Certified Public Accountant while working at Coopers & Lybrand.

“What attracted me to Homology Medicines is the proprietary gene editing and gene therapy technology platform that utilizes homologous recombination, a naturally occurring biological mechanism, and an executive team with demonstrated success in turning scientific concepts into treatments for patients with rare genetic diseases,” said Mr. Smith. “This unique mix of technology and talent positions Homology Medicines with significant competitive advantages relative to other genetic medicine approaches. I look forward to working with the team at Homology Medicines and the strong existing investor base to bring the pipeline of potential new treatments and cures for genetic diseases to the patients who need them.”

About Homology Medicines, Inc.

​Homology Medicines is a genetic medicines company translating proprietary, next generation gene editing and gene therapy technologies into novel treatments for patients with rare diseases. The combination of a new multidimensional technology platform and a management team that has successfully developed and commercialized rare disease therapies uniquely positions the Company to move beyond the current limitations of gene therapy and gene editing approaches to improve patient care. Homology Medicines has built foundational intellectual property on gene editing and gene therapy using vectors derived from naturally occurring human adeno-associated viruses (AAVs). The Company’s technology is precise, on-target and highly efficient for in vivo editing of genetic mutations. The unique team and technology create a significant opportunity for Homology Medicines to rapidly advance a diverse pipeline of new medicines that address and potentially cure the underlying cause of genetic diseases. For more information, please visit www.homologymedicines.com.

Cara Mayfield
Director, Corporate Communications
781-301-7277, ext. 141